Indomethacin Capsule
Product Images NDC 50268-430

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Indomethacin (NDC 50268-430). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

A (Table 1a)

A data table listing adverse reactions to Indomethacin capsules, organized by incidence greater than 1% and less than 1%. It categorizes reactions under Gastrointestinal and Central Nervous System effects, detailing specific symptoms such as nausea, headache, anxiety, and others with their approximate incidence.*

FDA Label Image

B (Table1b)

This image displays a text panel listing adverse reactions associated with Indomethacin capsules organized by system categories: Special Senses, Cardiovascular, Metabolic, Integumentary, and Hematologic. Each category details specific conditions reported, ranging from tinnitus and ocular disturbances to cardiovascular issues like hypertension, metabolic effects such as edema, skin reactions, and hematologic abnormalities including leucopenia and anemia.*

FDA Label Image

C (Table1c)

A text panel listing adverse reactions associated with Indomethacin capsules. Categories covered include hypersensitivity reactions (such as acute anaphylaxis and pulmonary edema), genitourinary effects (including hematuria and renal insufficiency), and miscellaneous effects like epistaxis and breast changes. The panel notes these reactions occur in 3% to 9% of patients.*

FDA Label Image

A (Table 2a)

This text panel details clinical impacts and interventions for drugs that interfere with hemostasis, aspirin, and ACE inhibitors, angiotensin receptor blockers, and beta-blockers. It provides specific interactions and warnings related to the use of indomethacin and anticoagulants, aspirin, and various antihypertensive agents, highlighting risk factors and clinical study findings concerning bleeding and therapeutic effectiveness.*

FDA Label Image

B (Table 2b)

A text panel detailing clinical impact and intervention guidelines for the concomitant use of indomethacin with other drugs including ACE-inhibitors, ARBs, beta-blockers, diuretics, digoxin, and lithium. It discusses monitoring blood pressure, renal function, serum potassium, and digoxin levels during combined use. The text also highlights risks of renal impairment and drug interactions with specific warnings.*

FDA Label Image

C (Table 2c)

Text panel listing clinical impact and intervention guidelines for drug interactions involving indomethacin. It addresses interaction risks with lithium, methotrexate, cyclosporine, NSAIDs and salicylates, and pemetrexed, with emphasis on monitoring patients for toxicity and adverse effects during concomitant use.*

FDA Label Image

D (Table 2d)

A text panel with clinical intervention information related to indomethacin. It details monitoring and dosing considerations during concomitant use with pemetrexed in patients with renal impairment, and advises caution with NSAIDs based on their elimination half-lives. It also summarizes the clinical impact and dosing recommendations when indomethacin is coadministered with probenecid.*

FDA Label Image

Structure (Structure)

Chemical structure of indomethacin showing its molecular framework with labeled functional groups including methoxy, methyl, carboxylic acid, chloro, and amide linkages.*

FDA Label Image

50 (430 15)

Label for Indomethacin Capsules, USP 25 mg oral capsules by AvPAK. The packaging indicates prescription-only status and contains 50 capsules (5 blister packs of 10 unit doses). The label includes storage instructions, a dosage guide for adults, and a barcode. The manufacturer information and a QR code are also shown.*

FDA Label Image

50 (431 15)

Label for Indomethacin Capsules, USP, 50 mg strength, manufactured by AvPAK. The label specifies it is a prescription-only medication, packaged as 50 capsules in unit dose format (5 blister cards of 10 capsules each). It includes storage instructions, dosage guidance, a barcode, and the AvPAK logo at the bottom.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.